PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23275066-5	2013	Coincubation of clopidogrel with the CES1 inhibitor bis(4-nitrophenyl) phosphate in human liver s9 fractions significantly increased the concentrations of clopidogrel, 2-oxo-clopidogrel, and clopidogrel active metabolite, while the concentrations of all formed carboxylate metabolites were significantly decreased.	2-oxo-clopidogrel	168-185	carboxylesterase 1	Homo sapiens	37-41	
25747989-7	2015	Our in vitro human liver s9 fraction incubation study demonstrated that simvastatin significantly enhanced the formation of the intermediate metabolite 2-oxo-clopidogrel, and inhibited the CES1-mediated hydrolysis of clopidogrel, 2-oxo-clopidogrel, and the active metabolite.	2-oxo-clopidogrel	230-247	carboxylesterase 1	Homo sapiens	189-193	
23275066-6	2013	As anticipated, clopidogrel and 2-oxo-clopidogrel were efficiently hydrolyzed by the cell s9 fractions prepared from wild-type CES1 transfected cells.	2-oxo-clopidogrel	32-49	carboxylesterase 1	Homo sapiens	127-131	
23275066-7	2013	The enzymatic activity of the CES1 variants G143E and D260fs were completely impaired in terms of catalyzing the hydrolysis of clopidogrel and 2-oxo-clopidogrel.	2-oxo-clopidogrel	143-160	carboxylesterase 1	Homo sapiens	30-34